• Understanding & Preventing FVIII Inhibitors : An Enduring HA Research Priority

  • Aug 1 2024
  • Length: 1 hr and 9 mins
  • Podcast

Understanding & Preventing FVIII Inhibitors : An Enduring HA Research Priority

  • Summary

  • On this episode of the Global Hemophilia Report, Senior Advisor Dr. Donna DiMichele leads a comprehensive discussion on FVIII inhibitors—a critical complication in Hemophilia A. The episode features experts such as Dr. Kathleen Pratt, Dr. David Lillicrap, Dr. Bhavya Doshi, Dr. Carol Miao, and Dr. Radek Kazmarek who explore the intricacies of immune responses, gene therapy, and novel therapies like emicizumab. They delve into factors like antigen-presenting cells, B cells, T cells, microbiome effects, and glycans that influence inhibitor development and tolerance. Despite advancements in treatment, the experts underscore the enduring importance of ongoing research in understanding and preventing FVIII inhibitors.

    Contributors:

    Glaivy Batsuli, MD

    Bhavya Doshi, MD

    David Lillicrap, MD

    Carol Miao, PhD

    Kathleen Pratt, PhD

    Radek Kaczmarek, PhD

    Senior Advisor: Donna DiMichele, MD

    Hosted & Written by: Patrick James Lynch

    Featured Advertiser:

    Sanofi

    Subscribe to the Global Hemophilia Report

    Show Notes:

    Listen to the Global Hemophilia Report Episode 1: Inhibitors: Prevention, Eradication, and Lived Experiences

    Conflicts of Interest: Dr. Kathleen Pratt is an inventor on patents related to factor VIII immunogenicity, and she has received research funding in the past from pharmaceutical companies that manufacture human FVIII. She has no other relevant conflicts to report.

    Disclaimer: The contents of Dr. Pratt's presentation are the sole responsibility of the speaker and do not necessarily reflect the views, opinions or policies of Uniformed Services University of the Health Sciences (USUHS), The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of Defense (DoD) or the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government.

    Connect with the Global Hemophilia Report

    Global Hemophilia Report on LinkedIn

    Global Hemophilia Report on Twitter

    Global Hemophilia Report on Facebook

    Connect with BloodStream Media:

    BloodStreamMedia.com

    BloodStream on Facebook

    BloodStream on Twitter

    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2
activate_samplebutton_t1

What listeners say about Understanding & Preventing FVIII Inhibitors : An Enduring HA Research Priority

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.